Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Merck VP Joan Butterton
Joan Butterton oversees antibiotic development at Merck. • Source: Merck & Co. Inc.

More from Anti-infective

More from Therapy Areas